Monitoring ovarian cancer prognosis after standard treatment
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Via Analysis of Immunoinflammation-related Protein Complexes in Blood
This study looks at blood proteins in women with ovarian cancer to see if they can help predict if the cancer will come back or spread after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | Female |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05410015 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the relationship between immune inflammation-related protein complexes in the blood and the recurrence or metastasis of ovarian cancer. It involves analyzing 300 cases divided into three groups: normal ovarian control, benign ovarian disease, and malignant ovarian epithelial carcinoma. The study aims to identify changes in specific protein complexes associated with ovarian cancer and their correlation with the patients' pathological states.
Who should consider this trial
Good fit: Ideal candidates for this study are females with normal ovaries, benign ovarian diseases, or malignant ovarian epithelial carcinoma.
Not a fit: Patients who are male, over the age of 70, suffering from other malignant tumors, or non-compliant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance prognostic monitoring for women who have completed treatment for ovarian cancer, potentially leading to better management of recurrence.
How similar studies have performed: While the specific approach of this study may be novel, similar studies have shown promise in understanding the prognostic factors in ovarian cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female * Normal ovary control * Ovarian benign disease * Ovarian malignant epithelial carcinoma Exclusion Criteria: * Male * Age above 70 * Suffering from other malignant tumors * Non-compliant patient
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Peng Peng, MD
- Email: pengp1999@163.com
- Phone: +86-13521361934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.